RecruitingPhase 2NCT05922761

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Studying Bronchiolitis obliterans

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Dana-Farber Cancer Institute
Principal Investigator
Corey Cutler, MD, MPH, F.N.P
Dana-Farber Cancer Institute
Intervention
Belumosudil(drug)
Enrollment
45 enrolled
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (5)

Collaborators

Sanofi · National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05922761 on ClinicalTrials.gov

Other trials for Bronchiolitis obliterans

Additional recruiting or active studies for the same condition.

See all trials for Bronchiolitis obliterans

← Back to all trials